Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus adjuvant chemotherapy versus chemotherapy alone after surgery for HER2-positive stage IB-II gastric cancer
ChiCTR2600132821Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Xijing Hospital. Primary endpoint: 5-year disease-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600132821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132821.